We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antibody Clears Amyloid Plaques in Mouse Model

By LabMedica International staff writers
Posted on 10 Apr 2018
A team of Alzheimer's disease researchers working with a mouse model identified a specific antibody capable of binding to and mediating the removal of the amyloid plaques that characterize this catastrophic neurodegenerative disorder.

The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor so far discovered for late-onset Alzheimer disease (LOAD). More...
Previous studies have provided evidence that apoE influenced Alzheimer disease (AD) in large part by affecting amyloid beta (Abeta) aggregation and clearance; however, the molecular mechanism underlying these findings remains largely unknown.

To increase understanding of the role of apoE in AD, investigators at Washington University School of Medicine (St. Louis, MO, USA) examined whether anti-human apoE antibodies could decrease Abeta pathology in mice producing both human Abeta and apoE4, and investigated the mechanism underlying these effects. To do this, the investigators utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4).

The investigators reported in the March 30, 2018, online edition of the Journal of Clinical Investigation that they had discovered an anti-human apoE antibody, anti-human apoE 4 (HAE-4), that specifically recognized human apoE4 and apoE3 and preferentially bound non-lipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also bound to apoE in amyloid plaques in unfixed brain sections and in living APPPS1-21/APOE4 mice.

When delivered centrally or by peripheral injection, HAE-4 reduced Abeta deposition in APPPS1-21/APOE4 mice. Using an adeno-associated virus vector to express two different full-length anti-apoE antibodies in the brain, they found that HAE antibodies decreased amyloid accumulation, which was dependent on Fcgamma receptor function.

These data tended to support the hypothesis that a primary mechanism for apoE-mediated plaque formation was a result of apoE aggregation, as preferentially targeting apoE aggregated with therapeutic antibodies reduced Abeta pathology and may represent a selective approach to treat AD.

“Many people build up amyloid over many years, and the brain just cannot get rid of it,” said senior author Dr. David Holtzman, professor of neurology at Washington University School of Medicine. “By removing plaques, if we start early enough, we may be able to stop the changes to the brain that result in forgetfulness, confusion, and cognitive decline.”

“It turns out that the APOE in the plaques has a different structure than the form of APOE found in the blood,” said Dr. Holtzman. “The anti-amyloid antibodies are going to be binding to most of the molecules that are in the plaque, but the anti-APOE antibody would target just a very small component of the plaque. This means we may find less immune activation, and we might not see the unwelcome side effects.”

Related Links:
Washington University School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.